GBLB Stock Analysis: Groep Brussel Lambert | BR

Asset Management | BR, Belgium | Market Cap: 8.936m EUR | 12M Return: 2.6% | BE0003797140 | Charts, Fundamentals & Technical Analysis

Investment Holding, Minerals, Bicycles, Healthcare
Total Rating 39
Safety 71
Buy Signal -0.45
Asset Management
Industry Rotation: +2.7
Market Cap: 10.4B
Avg Turnover: 5.65M
Risk 3d forecast
Volatility15.4%
VaR 5th Pctl2.85%
VaR vs Median12.5%
Reward TTM
Sharpe Ratio-0.04
Rel. Str. IBD16.1
Rel. Str. Peer Group22.5
Character TTM
Beta0.316
Beta Downside0.069
Hurst Exponent0.618
Drawdowns 3y
Max DD13.13%
CAGR/Max DD0.45
CAGR/Mean DD1.42
EPS (Earnings per Share) EPS (Earnings per Share) of GBLB over the last years for every Quarter: "2021-06": 2.14, "2021-09": 1.9, "2021-12": -0.37, "2022-03": 0.89, "2022-06": -2.23, "2022-09": -1.57, "2022-12": -4.52, "2023-03": 0.634, "2023-06": 0, "2023-09": 0, "2023-12": 0, "2024-03": 1.01, "2024-06": 0, "2024-09": 0, "2024-12": 0.57, "2025-03": 0.73, "2025-06": 0.34, "2025-09": 0, "2025-12": -5.2816, "2026-03": null, "2026-06": null,
Qual. Beats: 0
Revenue Revenue of GBLB over the last years for every Quarter: 2021-06: 1927, 2021-09: 1821.1, 2021-12: 1783.5, 2022-03: 1328.3, 2022-06: 2480.7, 2022-09: 1577.3, 2022-12: 2392.2, 2023-03: 1660.7, 2023-06: 1768.4, 2023-09: 1460.1, 2023-12: 1653.9, 2024-03: 1659.3, 2024-06: 1749, 2024-09: 1548, 2024-12: 1160.6, 2025-03: 1672.8, 2025-06: 1706.6, 2025-09: 132.6, 2025-12: 3182.9, 2026-03: 1740.2, 2026-06: 3665.8,
Rev. CAGR: 0.75%
Rev. Trend: 4.7%
Qual. Beats: 0

Warnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan -0.6% 5
Feb -0.3% 5
Mar +0.4% 5
Apr +1.3% 55
May +0.7% 18
Jun -0.6% 30
Jul +1.0% 34
Aug -0.1% 13
Sep -1.2% 19
Oct -2.0% 15
Nov -1.3% 15
Dec -0.1% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: GBLB Groep Brussel Lambert

Groupe Bruxelles Lambert (GBL) is a Belgian multi-sector holding company that invests in a diversified portfolio of industrial, consumer goods, and business service companies across Belgium, Europe, North America, and other international markets. The group operates through six reporting segments: Holding, Imerys (minerals-based specialty materials), Canyon, Affidea, Sanoptis, and GBL Capital together with Sienna Investment Managers, combining direct operating assets with asset management activities.

Founded in 1902 and headquartered in Brussels, GBL follows a long-established holding company model in which value is generated primarily through the active management of strategic equity stakes in operating subsidiaries and portfolio companies, supplemented by management and performance fees from its investment management arm. As a multi-sector holdings company within the Financials sector, GBLs earnings are typically driven by dividend income from investees, fair value changes on its investment portfolio, and the operating performance of consolidated subsidiaries, rather than from any single product line or geographic market.

Headlines to Watch Out For
  • Imerys margins soften on weaker European industrial demand
  • Affidea and Sanoptis drive healthcare segment NAV growth
  • Buyback program and portfolio disposals narrow discount to NAV
Piotroski VR-10 (Strict) 4.5
Net Income: -499.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.00 > 0.02 and ΔFCF/TA -2.64 > 1.0
NWC/Revenue: 21.20% < 20% (prev 44.97%; Δ -23.78% < -1%)
CFO/TA 0.03 > 3% & CFO 747.1m > Net Income -499.9m
Net Debt (6.93b) to EBITDA (767.0m): 9.04 < 3
Current Ratio: 4.44 > 1.5 & < 3
Outstanding Shares: last quarter (121.3m) vs 12m ago -6.88% < -2%
Gross Margin: 55.97% > 18% (prev 45.05%; Δ 10.93% > 0.5%)
Asset Turnover: 35.22% > 50% (prev 23.84%; Δ 11.38% > 0%)
Interest Coverage Ratio: 0.08 > 6 (EBIT TTM 26.2m / Interest Expense TTM 316.8m)
Altman Z'' 2.26
A: 0.08 (Total Current Assets 2.39b - Total Current Liabilities 537.9m) / Total Assets 24.0b
B: 0.24 (Retained Earnings 5.76b / Total Assets 24.0b)
C: 0.00 (EBIT TTM 26.2m / Avg Total Assets 24.8b)
D: 0.92 (Book Value of Equity 10.7b / Total Liabilities 11.6b)
Altman-Z'' = 2.26 = BBB
Beneish M -2.99
DSRI: 0.77 (Receivables 838.1m/756.1m, Revenue 8.72b/6.09b)
GMI: 0.80 (GM 45.05% / 55.97%)
AQI: 1.16 (AQ_t 0.75 / AQ_t-1 0.65)
SGI: 1.43 (Revenue 8.72b / 6.09b)
TATA: -0.05 (NI -499.9m - CFO 747.1m) / TA 24.0b)
Beneish M = -2.99 (Cap -4..+1) = A
What is the price of GBLB shares?

As of August 23, 2026, the stock is trading at EUR 73.05 with a total of 97,408 shares traded. Over the past week, the price has changed by -2.40%, over one month by -5.38%, over three months by -8.80% and over the past year by +2.64%.

Current recommended Stop Loss: 71.50 (which is 2.1% or 1.5 ATR below the current price).

Is GBLB a buy, sell or hold?

Groep Brussel Lambert has no consensus analysts rating.

Groep Brussel Lambert (GBLB) - Fundamental Data Overview as of 17 August 2026
Market Cap USD = 10.4b (8.94b EUR * 1.1687 EUR.USD)
P/E Forward = 25.7069
P/S = 1.3475
P/B = 0.8324
P/EG = 0.5212
Revenue TTM = 8.72b EUR
EBIT TTM = 26.2m EUR
EBITDA TTM = 767.0m EUR
Long Term Debt = 6.34b EUR (from longTermDebt, last quarter)
Short Term Debt = 537.9m EUR (from shortTermDebt, last quarter)
Debt = 8.48b EUR (from shortLongTermDebtTotal, last quarter) + Leases 867.9m
Net Debt = 6.93b EUR (calculated: Debt 8.48b - CCE 1.55b)
Enterprise Value = 15.9b EUR (8.94b + Debt 8.48b - CCE 1.55b)
Interest Coverage Ratio = 0.08 (Ebit TTM 26.2m / Interest Expense TTM 316.8m)
EV/FCF = 230.0x (Enterprise Value 15.9b / FCF TTM 69.0m)
FCF Yield = 0.43% (FCF TTM 69.0m / Enterprise Value 15.9b)
FCF Margin = 0.79% (FCF TTM 69.0m / Revenue TTM 8.72b)
Net Margin = -5.73% (Net Income TTM -499.9m / Revenue TTM 8.72b)
Gross Margin = 55.97% ((Revenue TTM 8.72b - Cost of Revenue TTM 3.84b) / Revenue TTM)
Gross Margin QoQ = 53.18% (prev 72.41%)
Tobins Q-Ratio = 0.66 (Enterprise Value 15.9b / Total Assets 24.0b)
Interest Expense / Debt = 3.74% (Interest Expense 316.8m / Debt 8.48b)
Taxrate = 32.01% (33.9m / 105.9m)
NOPAT = 17.8m (EBIT 26.2m * (1 - 32.01%))
Current Ratio = 4.44 (Total Current Assets 2.39b / Total Current Liabilities 537.9m)
Debt / Equity = 0.79 (Debt 8.48b / totalStockholderEquity, last quarter 10.7b)
Debt / EBITDA = 9.04 (Net Debt 6.93b / EBITDA 767.0m)
Debt / FCF = 100.5 (Net Debt 6.93b / FCF TTM 69.0m)
Total Stockholder Equity = 12.5b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.02% (Net Income -499.9m / Total Assets 24.0b)
RoE = -4.00% (Net Income TTM -499.9m / Total Stockholder Equity 12.5b)
RoCE = 0.14% (EBIT 26.2m / Capital Employed (Equity 12.5b + L.T.Debt 6.34b))
RoIC = 0.08% (NOPAT 17.8m / Invested Capital 23.6b)
WACC = 4.87% (E(8.94b)/V(17.4b) * Re(7.09%) + D(8.48b)/V(17.4b) * Rd(3.74%) * (1-Tc(0.32)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -61.59 | Cagr: -6.06%
[DCF] Terminal Value 73.10% ; FCFF base≈340.2m ; Y1≈298.3m ; Y5≈241.0m
 [DCF] Fair Price = N/A (negative equity: EV 3.87b - Net Debt 6.93b = -3.06b; debt exceeds intrinsic value)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 4.71 | Revenue CAGR: 0.75% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2.82 | Chg30d=+20.00% | Revisions=+25% | GrowthEPS=-1.4% | GrowthRev=+2.6%
EPS next Year (2027-12-31): EPS=2.83 | Chg30d=+19.41% | Revisions=+25% | GrowthEPS=+0.4% | GrowthRev=+3.0%